Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 33Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 11Triple Negative Breast Neoplasms 3Recurrence 3Esophageal Squamous Cell Carcinoma 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Unspecified Adult Solid Tumor, Protocol Specific 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Primary Breast Cancer 1Pathologic Residual Cancer Cells 1Ovarian Neoplasms 1Osteosarcoma 1Nonhematologic Malignancies 1Non-small Cell Lung Cancer Stage â…¡ 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplasms, Connective and Soft Tissue 1Neoplasm Metastasis 1NSCLC 1

Interventions

margetuximab 1apatinib 1Vinorelbine 1Trastuzumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Cancer Metastatic × Vinorelbine × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡